Clinical Research Directory

QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient

Raltegravir (RAL) is a very effective antiretroviral drug with a favorable long term tolerability. RAL offers many advantages such as lack of drug-drug interactions, a good safety profile particularly on lipids, inflammation and bone parameters. Ral can be an very interesting for patient with comorbidities and comedications, intolerance or toxicities with their current ARV treatment. However its current formulation of one tablet of 400mg twice a day coul not suit many patients. A new once-a-day formulation of RAL has been developed, with two tablets of 600 mg QD. Pharmacokinetic study in healthy volunteers has shown that this dosing provides increased RAL exposure compared to the standard formulation of 400 mg given twice a day. The objective of this study is to evaluate the maintain of virologic suppression with raltegravir 600mg 2 tablets qd as part of a triple antiretroviral regimen in virologically controlled patients.

Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75

Since the advent of antiretroviral treatments, the life expectancy of people living with HIV (PLHIV) has increased significantly. In France, more than 30% of PLHIV are now over 50 years old. This population is exposed to high multimorbidity, leading to frequent polypharmacy, defined as the regular use of at least five medications. Polypharmacy also has a qualitative dimension, including potentially inappropriate prescriptions. It increases the risk of adverse effects and drug interactions and impairs quality of life. A coordinated geriatric approach is therefore essential to optimize care. Healthy aging, promoted by the WHO, aims to improve the lives of older people. In this context, a study will be conducted at the Nice University Hospital among PLHIV aged 75 and over. It will collect quantitative data, the results of which will enable us to consider, if necessary, adapting the care pathways of these patients whose needs are complex.

Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV

Missed opportunity to pre-exposure prophylaxis is a survey study that will be addressed to newly infected with human immunodeficiency virus (HIV) persons. The purposes of this study is to understand why despite the fact that pre-exposure prophylaxis exist, these persons have been contaminated with HIV.